XML 48 R38.htm IDEA: XBRL DOCUMENT v3.25.1

Segments (Tables)

3 Months Ended

Mar. 31, 2025

Summary of Segment Profit

a. Segment information:

		Three months ended March 31,
		2025
		United States				Europe				International Markets
		(U.S. $ in millions)
Revenues		$	1,910			$	1,194			$	582
Cost of sales			851				536				304
R&D expenses			154				60				25
S&M expenses			273				199				118
G&A expenses			96				69				39
Other			3				§				(1	)
Segment profit		$	532			$	329			$	97

§ Represents an amount less than $0.5 million.

		Three months ended March 31,
		2024
		United States				Europe				International Markets
		(U.S. $ in millions)
Revenues		$	1,725			$	1,272			$	597
Cost of sales			867				534				300
R&D expenses			154				56				28
S&M expenses			261				194				118
G&A expenses			93				65				35
Other			1				1				§
Segment profit		$	350			$	423			$	117

§ Represents an amount less than $0.5 million.

The following table presents a reconciliation of Teva’s segment profits to its consolidated operating income (loss) and to consolidated income (loss) before income taxes for the three months ended March 31, 2025 and 2024:

		Three months ended
		March 31,
		2025				2024
		(U.S. $ in millions)
United States profit		$	532			$	350
Europe profit			329				423
International Markets profit			97				117
Total reportable segments profit			958				890
Profit (loss) of other activities			(13	)			2
Amounts not allocated to segments:
Amortization			145				152
Other assets impairments, restructuring and other items			(22	)			673
Intangible assets impairments			121				80
Legal settlements and loss contingencies			83				106
Other unallocated amounts			99				99
Consolidated operating income (loss)			519				(218	)
Financial expenses, net			225				250
Consolidated income (loss) before income taxes		$	294			$	(467	)

Schedule Of Consolidated Income Before Income Tax

The following tables present revenues by major products and activities for the three months ended March 31, 2025 and 2024:

United States		Three months ended March 31,
		2025				2024
		(U.S. $ in millions)
Generic products (including biosimilars)		$	849			$	808
AJOVY®			53				45
AUSTEDO			396				282
BENDEKA® and TREANDA®			36				46
COPAXONE			54				30
UZEDY			39				15
Anda			373				381
Other			109				117
Total		$	1,910			$	1,725

Europe		Three months ended March 31,
		2025				2024
		(U.S. $ in millions)
Generic products (including OTC and biosimilars)		$	989			$	1,004
AJOVY			58				51
COPAXONE			42				57
Respiratory products			55				66
Other			50				94
Total		$	1,194			$	1,272

International markets		Three months ended March 31,
		2025				2024
		(U.S. $ in millions)
Generic products (including OTC and biosimilars)		$	468			$	477
AJOVY			28				17
AUSTEDO			15				14
COPAXONE			10				12
Other*			61				77
Total		$	582			$	597

* Other revenues in the first quarter of 2025 include the sale of certain product rights.

X

- Definition

Schedule of consolidated income before income tax.

+ References

No definition available.

+ Details

Name:	teva_ScheduleOfConsolidatedIncomeBeforeIncomeTaxTableTextBlock
Namespace Prefix:	teva_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-31

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

+ Details

Name:	us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration